Zimbabwe has turned down a major US health deal valued at $367m (272 million pounds) over five years due to the United States' request for sensitive information.
This rejection became public following a internal memorandum dated December was leaked, indicating that President Emmerson Mnangagwa deemed the agreement was "lopsided".
A government spokesperson later explained that the United States was seeking biological samples for research and commercial gain but was not willing to share the benefits from future vaccines.
"We must now begin the difficult and regrettable process of winding down our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the US had donated more than $1.9bn in health funding to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has urged further dialogue to secure a agreement agreeable to both sides so the country's vital HIV treatment initiative can continue.
Wider Context
This development comes after a similar case in neighbouring Kenya, where a high court suspended a similar deal with the US following legal challenges were filed about the safety of citizens' health data.
Since returning to the presidency recently, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
USAID had overseen aid for the US government, but Trump claimed its expenditure was "wasteful" and his government was seeking direct bilateral agreements to enhance transparency and responsibility.
As per statements, Sixteen African countries have to date signed similar agreements, representing more than $18.3bn of fresh investment.
Details of the Declined Deal
This assistance for Zimbabwe was intended to funded "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"It is our view this cooperation would have delivered immense advantages for the people of Zimbabwe, especially the 1.2 million currently on HIV treatment through US-supported initiatives," Tremont commented.
However, government spokesperson Nick Mangwana said the proposed deal was "unequal".
"Zimbabwe was being asked to provide its biological resources and data for a long time, without any corresponding promise of access to any medical innovations – like vaccines, diagnostics, or treatments – that could be developed from that shared data," Mangwana explained.
"In essence, our nation would provide the basic resources for medical research without any assurance that the end products would be accessible to our people if a new pandemic arise."
National Interest and Global Health
He also pointed out that the American exit from the global health body and its push of one-on-one health agreements were disrupting frameworks already established via the international organization.
Mangwana cited its Pandemic Benefit-Sharing system created to deal with potential pandemics.
"This system is intended to guarantee that when a country contributes its data, the resulting advantages – such as vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the capability to develop them."
These objections over the US deal "should not be misconstrued as anti-American sentiment," he added.
"We encourage further dialogue with our American counterparts on how subsequent co-operation might be arranged in a way that honours the sovereignty and dignity of both nations."
Medical Community Response
A leading public health body said it understood the government's concerns, but suggested that talks must proceed given that much of the nation's HIV programmes depended on external financing.
"In cases where technical issues exist, such as those relating to data governance or agreement terms, these can often be resolved via detailed discussion and negotiated safeguards," it added.
This impasse highlights the continuing debate between receiving much-needed foreign assistance and safeguarding national sovereignty in an increasingly interconnected world.